ULBP1, 2, 3: novel MHC class I-related molecules that bind to human cytomegalovirus glycoprotein UL16, activate NK cells.

Kubin, M ; Cassiano, L ; et al.

In: European journal of immunology, Jg. 31 (2001-05-01), Heft 5, S. 1428-37

Online academicJournal

Zugriff:

Full Text Finder (Volltext)

New members of the extended MHC class I-like family were identified based on their ability to bind human cytomegalovirus glycoprotein UL16 and/or their mutual homology. Soluble UL16 binding proteins (ULBP) competed with each other for binding to NK cells. Treatment of human and mouse NK cells with ULBP led to increased production of cytokines/chemokines, proliferation, cytotoxic activity and up-regulation of activation-associated surface molecules. The presence of ULBP during the stimulation phase of the CTL assay caused increased cytotoxic activity. Addition of soluble recombinant UL16 protein inhibited the biological activities mediated by ULBP, suggesting the existence of a novel mechanism utilized by CMV to evade elimination by the host immune system.

Titel:	ULBP1, 2, 3: novel MHC class I-related molecules that bind to human cytomegalovirus glycoprotein UL16, activate NK cells.
Autor/in / Beteiligte Person:	Kubin, M ; Cassiano, L ; Chalupny, J ; Chin, W ; Cosman, D ; Fanslow, W ; Müllberg, J ; Rousseau, AM ; Ulrich, D ; Armitage, R
Link:	Full Text Finder (Volltext) E-Journal im Bestand der UB Hagen?
Zeitschrift:	European journal of immunology, Jg. 31 (2001-05-01), Heft 5, S. 1428-37
Veröffentlichung:	<2005->: Weinheim : Wiley-VCH ; <i>Original Publication</i>: Weinheim, Verlag Chemie GmbH., 2001
Medientyp:	academicJournal
ISSN:	0014-2980 (print)
DOI:	10.1002/1521-4141(200105)31:5<1428::AID-IMMU1428>3.0.CO;2-4
Schlagwort:	Animals Binding, Competitive Carrier Proteins antagonists & inhibitors Cell Division drug effects Cells, Cultured Chemokines metabolism Cytokines metabolism Cytomegalovirus immunology Cytotoxicity, Immunologic Flow Cytometry GPI-Linked Proteins Humans Immunoglobulin G immunology Intercellular Signaling Peptides and Proteins Interleukin-15 immunology Intracellular Signaling Peptides and Proteins Killer Cells, Natural cytology Killer Cells, Natural drug effects Killer Cells, Natural metabolism Lymphocyte Count Membrane Proteins Mice Mice, SCID Protein Binding Solubility Spleen cytology T-Lymphocytes, Cytotoxic immunology Viral Envelope Proteins pharmacology Carrier Proteins metabolism Cytomegalovirus metabolism Histocompatibility Antigens Class I metabolism Killer Cells, Natural immunology Lymphocyte Activation drug effects Viral Envelope Proteins metabolism
Sonstiges:	Nachgewiesen in: MEDLINE Sprachen: English Publication Type: Journal Article Language: English [Eur J Immunol] 2001 May; Vol. 31 (5), pp. 1428-37. MeSH Terms: Lymphocyte Activation* / drug effects ; Carrier Proteins / metabolism ; Cytomegalovirus / metabolism ; Histocompatibility Antigens Class I / metabolism ; Killer Cells, Natural / immunology ; Viral Envelope Proteins / *metabolism ; Animals ; Binding, Competitive ; Carrier Proteins / antagonists & inhibitors ; Cell Division / drug effects ; Cells, Cultured ; Chemokines / metabolism ; Cytokines / metabolism ; Cytomegalovirus / immunology ; Cytotoxicity, Immunologic ; Flow Cytometry ; GPI-Linked Proteins ; Humans ; Immunoglobulin G / immunology ; Intercellular Signaling Peptides and Proteins ; Interleukin-15 / immunology ; Intracellular Signaling Peptides and Proteins ; Killer Cells, Natural / cytology ; Killer Cells, Natural / drug effects ; Killer Cells, Natural / metabolism ; Lymphocyte Count ; Membrane Proteins ; Mice ; Mice, SCID ; Protein Binding ; Solubility ; Spleen / cytology ; T-Lymphocytes, Cytotoxic / immunology ; Viral Envelope Proteins / pharmacology Substance Nomenclature: 0 (Carrier Proteins) ; 0 (Chemokines) ; 0 (Cytokines) ; 0 (GPI-Linked Proteins) ; 0 (Histocompatibility Antigens Class I) ; 0 (Immunoglobulin G) ; 0 (Intercellular Signaling Peptides and Proteins) ; 0 (Interleukin-15) ; 0 (Intracellular Signaling Peptides and Proteins) ; 0 (Membrane Proteins) ; 0 (ULBP1 protein, human) ; 0 (ULBP2 protein, human) ; 0 (ULBP3 protein, human) ; 0 (Viral Envelope Proteins) Entry Date(s): Date Created: 20010724 Date Completed: 20010809 Latest Revision: 20101118 Update Code: 20231215

Klicken Sie ein Format an und speichern Sie dann die Daten oder geben Sie eine Empfänger-Adresse ein und lassen Sie sich per Email zusenden.

BibTeX Citavi, JabRef, u.a.
(Literaturverwaltung)

PDF kein Volltext!
(Merkzettel, Notizen)

RIS Endnote, Citavi u.a.
(Literaturverwaltung)

MODS
(XML zur Weiterverarbeitung)

oder

Wählen Sie das für Sie passende Zitationsformat und kopieren Sie es dann in die Zwischenablage, lassen es sich per Mail zusenden oder speichern es als PDF-Datei.

Gewünschter Zitations-Stil:

oder

Bitte prüfen Sie, ob die Zitation formal korrekt ist, bevor Sie sie in einer Arbeit verwenden. Benutzen Sie gegebenenfalls den "Exportieren"-Dialog, wenn Sie ein Literaturverwaltungsprogramm verwenden und die Zitat-Angaben selbst formatieren wollen.